Reyiena Kusumaryani Rahmat
Biopath Laboratory, Bandung, Indonesia.

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

Characterization of FOLR2 Expression on Tumor-Associated Macrophages (TAMs) Across Breast Cancer Molecular Subtypes in Bandung Meike Rachmawati; Muhammad Syah Misuari Sabirin; Ismet Muchtar Nur; Meta Maulida Damayanti; Rian Robian; Adhi Nugraha Hadinata; Aryanti; Rina Melati; Faradilla Azzahra Dinariansyah; Nabilah Yahdiani Darmawan; Aninditya Putri Anugrah; Reyiena Kusumaryani Rahmat; Yatasya Aulia
Bandung Conference Series: Medical Science 1537-1546
Publisher : UNISBA Press

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.29313/bcsms.v5i3.21657

Abstract

Abstract. Breast cancer is a heterogeneous disease and a leading cause of death in women worldwide. The tumor microenvironment (TME), which includes tumor-associated macrophages (TAMs), plays a key role in its progression. Folate Receptor 2 (FOLR2) is a marker of M2 macrophages and is associated with pro-tumor activity. Previous studies have shown increased FOLR2 expression on TAMs in various cancers, including breast cancer, which has been linked to poor clinical outcomes. This study aimed to characterize FOLR2 expression on TAMs in breast cancer subtypes and evaluate its potential as a diagnostic and prognostic marker. Immunohistochemistry (IHC) results of FOLR2⁺ TAMs, which are expressed as the immunoreactive score (IRS), were analyzed across three molecular subtypes of breast cancer (TNBC, Luminal, and HER2-enriched). Kruskal–Wallis analysis demonstrated significant differences in FOLR2 expression among the subtypes. The mean ± SD IRS values were TNBC = 3.81 ± 1.16, HER2-enriched = 2.42 ± 1.73, and Luminal = 2.18 ± 1.54. Post hoc Dunn’s test revealed that the difference was statistically significant between TNBC and Luminal subtypes (p < 0.05), whereas no significant difference was observed between TNBC and HER2-enriched, or between Luminal and HER2-enriched subtypes. Fisher’s exact test revealed a statistically significant association between molecular subtype and FOLR2 expression in breast cancer (p-value < 0.05). Spatial analysis further showed that FOLR2 was predominantly expressed in peritumoral areas, particularly around blood vessels and adipose tissue, while its expression in the intratumoral stroma was relatively lower. These findings suggest that FOLR2 expression on TAMs varies among breast cancer molecular subtypes, with TNBC showing the highest levels, and that its spatial distribution within the TME may contribute to tumor progression, therefore highlights the potential of FOLR2 as a diagnostic and prognostic biomarker in breast cancer.